Metallothioneins and resistance to cisplatin and radiation in prostate cancer

David J. Smith, Meena Jaggi, Wenguang Zhang, Anton Galich, Cheng Du, Samuel P. Sterrett, Lynette M Smith, K. C. Balaji

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives: The metallothioneins (MTs) are a family of small molecular weight trace metal and free radical scavenging proteins well established to play a role in the resistance to chemotherapy and radiotherapy in human cancers. MT gene expression is upregulated in response to the presence of metal ions such as zinc. Because prostatic tissue has the greatest concentration of zinc in the human body, in this study we analyzed the effect of MT induction by zinc in prostate cancer (PCa). Methods: The activation of MT gene expression in response to zinc treatment in LNCaP and C4-2 PCa cells was shown by Western blotting and DNA microarray analysis. Chemotherapy and radiation sensitivity assays of cells after treatment with cisplatin or radiation were performed in the presence, or absence, of 150 μM ZnSO4, and cell viability was measured after 72 hours by MTS viability and clonogenic and flow cytometry assays. The experiments were repeated three times and the data analyzed. Results: Increasing concentrations of ZnSO4 upregulated MT expression in a dose-dependent manner. Microarray analysis demonstrated a specific increase in MT expression. Cells treated with zinc demonstrated a significantly decreased sensitivity to cisplatin and radiotherapy compared with controls (P <0.05). Conclusions: Our data have confirmed that treatment of PCa with zinc causes an increase in MT expression, which is significantly associated with resistance to cisplatin chemotherapy and radiotherapy in PCa. Therapeutic targeting of MT may therefore provide a means to overcome resistance to radiotherapy and cisplatin chemotherapy in PCa.

Original languageEnglish (US)
Pages (from-to)1341-1347
Number of pages7
JournalUrology
Volume67
Issue number6
DOIs
StatePublished - Jun 1 2006

Fingerprint

Metallothionein
Cisplatin
Zinc
Prostatic Neoplasms
Radiation
Radiotherapy
Drug Therapy
Microarray Analysis
Metals
Gene Expression
Radiation Tolerance
Therapeutics
Oligonucleotide Array Sequence Analysis
Human Body
Free Radicals
Cell Survival
Flow Cytometry
Molecular Weight
Western Blotting
Ions

ASJC Scopus subject areas

  • Urology

Cite this

Smith, D. J., Jaggi, M., Zhang, W., Galich, A., Du, C., Sterrett, S. P., ... Balaji, K. C. (2006). Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology, 67(6), 1341-1347. https://doi.org/10.1016/j.urology.2005.12.032

Metallothioneins and resistance to cisplatin and radiation in prostate cancer. / Smith, David J.; Jaggi, Meena; Zhang, Wenguang; Galich, Anton; Du, Cheng; Sterrett, Samuel P.; Smith, Lynette M; Balaji, K. C.

In: Urology, Vol. 67, No. 6, 01.06.2006, p. 1341-1347.

Research output: Contribution to journalArticle

Smith, DJ, Jaggi, M, Zhang, W, Galich, A, Du, C, Sterrett, SP, Smith, LM & Balaji, KC 2006, 'Metallothioneins and resistance to cisplatin and radiation in prostate cancer', Urology, vol. 67, no. 6, pp. 1341-1347. https://doi.org/10.1016/j.urology.2005.12.032
Smith DJ, Jaggi M, Zhang W, Galich A, Du C, Sterrett SP et al. Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology. 2006 Jun 1;67(6):1341-1347. https://doi.org/10.1016/j.urology.2005.12.032
Smith, David J. ; Jaggi, Meena ; Zhang, Wenguang ; Galich, Anton ; Du, Cheng ; Sterrett, Samuel P. ; Smith, Lynette M ; Balaji, K. C. / Metallothioneins and resistance to cisplatin and radiation in prostate cancer. In: Urology. 2006 ; Vol. 67, No. 6. pp. 1341-1347.
@article{6c1cc61e35e740f98d225db994ae4732,
title = "Metallothioneins and resistance to cisplatin and radiation in prostate cancer",
abstract = "Objectives: The metallothioneins (MTs) are a family of small molecular weight trace metal and free radical scavenging proteins well established to play a role in the resistance to chemotherapy and radiotherapy in human cancers. MT gene expression is upregulated in response to the presence of metal ions such as zinc. Because prostatic tissue has the greatest concentration of zinc in the human body, in this study we analyzed the effect of MT induction by zinc in prostate cancer (PCa). Methods: The activation of MT gene expression in response to zinc treatment in LNCaP and C4-2 PCa cells was shown by Western blotting and DNA microarray analysis. Chemotherapy and radiation sensitivity assays of cells after treatment with cisplatin or radiation were performed in the presence, or absence, of 150 μM ZnSO4, and cell viability was measured after 72 hours by MTS viability and clonogenic and flow cytometry assays. The experiments were repeated three times and the data analyzed. Results: Increasing concentrations of ZnSO4 upregulated MT expression in a dose-dependent manner. Microarray analysis demonstrated a specific increase in MT expression. Cells treated with zinc demonstrated a significantly decreased sensitivity to cisplatin and radiotherapy compared with controls (P <0.05). Conclusions: Our data have confirmed that treatment of PCa with zinc causes an increase in MT expression, which is significantly associated with resistance to cisplatin chemotherapy and radiotherapy in PCa. Therapeutic targeting of MT may therefore provide a means to overcome resistance to radiotherapy and cisplatin chemotherapy in PCa.",
author = "Smith, {David J.} and Meena Jaggi and Wenguang Zhang and Anton Galich and Cheng Du and Sterrett, {Samuel P.} and Smith, {Lynette M} and Balaji, {K. C.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.urology.2005.12.032",
language = "English (US)",
volume = "67",
pages = "1341--1347",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Metallothioneins and resistance to cisplatin and radiation in prostate cancer

AU - Smith, David J.

AU - Jaggi, Meena

AU - Zhang, Wenguang

AU - Galich, Anton

AU - Du, Cheng

AU - Sterrett, Samuel P.

AU - Smith, Lynette M

AU - Balaji, K. C.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Objectives: The metallothioneins (MTs) are a family of small molecular weight trace metal and free radical scavenging proteins well established to play a role in the resistance to chemotherapy and radiotherapy in human cancers. MT gene expression is upregulated in response to the presence of metal ions such as zinc. Because prostatic tissue has the greatest concentration of zinc in the human body, in this study we analyzed the effect of MT induction by zinc in prostate cancer (PCa). Methods: The activation of MT gene expression in response to zinc treatment in LNCaP and C4-2 PCa cells was shown by Western blotting and DNA microarray analysis. Chemotherapy and radiation sensitivity assays of cells after treatment with cisplatin or radiation were performed in the presence, or absence, of 150 μM ZnSO4, and cell viability was measured after 72 hours by MTS viability and clonogenic and flow cytometry assays. The experiments were repeated three times and the data analyzed. Results: Increasing concentrations of ZnSO4 upregulated MT expression in a dose-dependent manner. Microarray analysis demonstrated a specific increase in MT expression. Cells treated with zinc demonstrated a significantly decreased sensitivity to cisplatin and radiotherapy compared with controls (P <0.05). Conclusions: Our data have confirmed that treatment of PCa with zinc causes an increase in MT expression, which is significantly associated with resistance to cisplatin chemotherapy and radiotherapy in PCa. Therapeutic targeting of MT may therefore provide a means to overcome resistance to radiotherapy and cisplatin chemotherapy in PCa.

AB - Objectives: The metallothioneins (MTs) are a family of small molecular weight trace metal and free radical scavenging proteins well established to play a role in the resistance to chemotherapy and radiotherapy in human cancers. MT gene expression is upregulated in response to the presence of metal ions such as zinc. Because prostatic tissue has the greatest concentration of zinc in the human body, in this study we analyzed the effect of MT induction by zinc in prostate cancer (PCa). Methods: The activation of MT gene expression in response to zinc treatment in LNCaP and C4-2 PCa cells was shown by Western blotting and DNA microarray analysis. Chemotherapy and radiation sensitivity assays of cells after treatment with cisplatin or radiation were performed in the presence, or absence, of 150 μM ZnSO4, and cell viability was measured after 72 hours by MTS viability and clonogenic and flow cytometry assays. The experiments were repeated three times and the data analyzed. Results: Increasing concentrations of ZnSO4 upregulated MT expression in a dose-dependent manner. Microarray analysis demonstrated a specific increase in MT expression. Cells treated with zinc demonstrated a significantly decreased sensitivity to cisplatin and radiotherapy compared with controls (P <0.05). Conclusions: Our data have confirmed that treatment of PCa with zinc causes an increase in MT expression, which is significantly associated with resistance to cisplatin chemotherapy and radiotherapy in PCa. Therapeutic targeting of MT may therefore provide a means to overcome resistance to radiotherapy and cisplatin chemotherapy in PCa.

UR - http://www.scopus.com/inward/record.url?scp=33744550703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744550703&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.12.032

DO - 10.1016/j.urology.2005.12.032

M3 - Article

VL - 67

SP - 1341

EP - 1347

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -